New insider activity at Precigen ( (PGEN) ) has taken place on September 26, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CFO Harry Jr. Thomasian has made a significant investment in Precigen by purchasing 11,216 shares of the company’s stock, valued at $40,015.
Recent Updates on PGEN stock
Recent developments for Precigen (PGEN) include the conversion of 79,000 shares of its Series A Convertible Perpetual Preferred Stock into over 54 million shares of common stock, executed without commission under an exemption from registration. Additionally, Precigen secured a $125 million loan facility from Pharmakon Advisors to support the commercialization of its novel immunotherapy, PAPZIMEOS, in the US and potentially internationally. These strategic moves have bolstered the company’s financial position and growth potential, despite ongoing concerns about financial stability and valuation. Analysts maintain a Hold rating with a $3.00 price target, reflecting strong technical momentum and positive corporate events, but tempered by financial performance concerns.
Spark’s Take on PGEN Stock
According to Spark, TipRanks’ AI Analyst, PGEN is a Neutral.
Precigen’s overall stock score reflects a mix of strong technical momentum and positive corporate events, offset by weak financial performance and valuation concerns. The company’s recent strategic moves and product approvals provide growth potential, but financial instability remains a significant risk.
To see Spark’s full report on PGEN stock, click here.
More about Precigen
YTD Price Performance: 222.69%
Average Trading Volume: 8,655,708
Technical Sentiment Signal: Buy
Current Market Cap: $1.15B